翰森制药25年上半年业绩超预期,公司上调全年指引,全球化进程持续推进

招商证券(香港)
Aug 20

2025上半年收入超出低双位数增长指引,得益于创新产品组合和BD合作。管理层重申25财年阿美乐销售目标为60亿元人民币管理层上调了2025财年指引,并预计到2030年将推出20款以上创新药维持增持,上调目标价至47.5元港币营收超预期,主要受益于肿瘤产品销售强劲和BD许可费首付款公司25财年上半年业绩强劲,营收同比增长14.3%至74亿元人民币,净利润同比增长15.0%至31亿元人民币,双双超出...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10